Health
Tessera Therapeutics Receives U.S. FDA Fast Track and Orphan Drug Designations for its Lead In Vivo Gene Editing Program TSRA-196 for the Treatment of Adults with AATD
SOMERVILLE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track and Orphan Drug designations to TSRA-196, its lead in vivo gene editing program. TSRA-196 is being jointly developed with Regeneron for the treatment of adults with alpha-1 antitrypsin deficiency (AATD) who are homozygous for the PiZ allele
About this update from Regeneron Pharmaceuticals, Inc.
[{"type":"image","alt":"Tessera Therapeutics","displaySize":"","headline":null,"caption":"Tessera Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":98,"url":"https://media.zenfs.com/en/globenewswire.com/2c6491d7d58f703fa0aa7855359d6814"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RkBEZVm.HcGy_GiwPtMRxQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2c6491d7d58f703fa0aa7855359d6814","width":300,"height":98}},"lazy":false},{"type":"text","content":"SOMERVILLE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing™, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track and Orphan Drug designations to TSRA-196, its lead in vivo gene editing program. TSRA-196 is being jointly developed with Regeneron for the treatment of adults with alpha-1 antitrypsin deficiency (AATD) who are homozygous for the PiZ allele (PiZZ).","length":512,"tagName":"p"},{"type":"text","content":"TSRA-196 is designed to precisely correct the genetic mutation underlying AATD, with the goal of restoring production of functional alpha-1 antitrypsin (AAT) protein through a one-time, durable treatment option for patients.","length":224,"tagName":"p"},{"type":"text","content":"“Despite a clear understanding of the mutation that drives severe AATD, options are limited to life-long treatments that fail to address the underlying cause of the disease,” said David Davidson, M.D., Chief Development and Medical Officer. “Based on compelling evidence to date, we believe that TSRA-196 has the potential to permanently correct the underlying mutation responsible for this debilitating disease and address a high unmet need for a durable therapy. Fast Track and Orphan designations allow us to accelerate the development of TSRA-196 to dramatically improve the lives of people living with AATD, and we look forward to translating this promising mechanism into meaningful outcomes in our ongoing global first-in-human trial.”","length":742,"tagName":"p"},{"type":"text","content":"Tessera recently initiated a Phase 1/2 trial to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. In this first-in-human, open-label, multi-national study, trial p...